Case Report
Lymph Node Metastasis after a Soft Tissue Sarcoma of the Leg: A Case Report and a Review of the Literature
Table 1
Four studies on the number of patients with a STS who develop RLNM.
| Type of tumor | Number of patients | Number of RLNMs | Percentage |
| Synovial sarcoma | | | | Mazeron and Suit [9] | 15 | 0 | 0% | Review Mazeron and Suit [9] | 851 | 117 | 14% | Fong et al. [10] | 145 | 2 | 1% | Daigeler et al. [11] | 111 | 4 | 4% | Behranwala et al. [12] | 171 | 7 | 4% |
|
Total | 1293 | 130 | 10% |
| Fibrosarcoma | | | | Mazeron and Suit [9] | 45 | 0 | 0% | Review Mazeron and Suit [9] | 215 | 54 | 25% | Fong et al. [10] | 162 | 0 | 0% | Daigeler et al. [11] | 45 | 1 | 2% | Behranwala et al. [12] | 132 | 1 | 1% |
| Total | 599 | 56 | 9% |
| Malignant fibrohistiocytoma | | | | Mazeron and Suit [9] | 48 | 1 | 2% | Review Mazeron and Suit [9] | 823 | 84 | 10% | Fong et al. [10] | 316 | 8 | 3% | Behranwala et al. [12] | 235 | 3 | 1% |
| Total | 1422 | 96 | 7% |
| Neurofibrosarcoma | | | | Mazeron and Suit [9] | 20 | 1 | 5% | Review Mazeron and Suit [9] | 476 | 3 | 1% | Fong et al. [10] | 96 | 2 | 2% | Daigeler et al. [11] | 94 | 3 | 3% | Behranwala et al. [12] | 95 | 4 | 4% |
| Total | 781 | 13 | 2% |
| Liposarcoma | | | | Mazeron and Suit [9] | 55 | 2 | 4% | Review Mazeron and Suit [9] | 504 | 16 | 3% | Fong et al. [10] | 403 | 3 | 1% | Daigeler et al. [11] | 333 | 1 | 0% | Behranwala et al. [12] | 340 | 3 | 1% |
| Total | 1635 | 25 | 2% |
| Rhabdomyosarcoma | | | | Mazeron and Suit [9] | 15 | 5 | 33% | Review Mazeron and Suit [9] | 1354 | 201 | 15% | Fong et al. [10] | 123 | 13 | 11% | Daigeler et al. [11] | 50 | 3 | 6% | Behranwala et al. [12] | 54 | 12 | 22% |
| Total | 1596 | 234 | 15% |
| Leiomyosarcoma | | | | Mazeron and Suit [9] | 30 | 1 | 3% | Review Mazeron and Suit [9] | 524 | 21 | 4% | Fong et al. [10] | 328 | 9 | 3% | Daigeler et al. [11] | 167 | 1 | 1% | Behranwala et al. [12] | 483 | 13 | 3% |
| Total | 1532 | 45 | 3% |
| Vascular sarcoma | | | | Mazeron and Suit [9] | 14 | 2 | 14% | Fong et al. [10] | 37 | 5 | 14% | Daigeler et al. [11] | 38 | 3 | 8% | Behranwala et al. [12] | 46 | 5 | 11% |
| Total | 135 | 15 | 11% |
| Epithelioid sarcoma | | | | Mazeron and Suit [9] | 7 | 5 | 71% | Review Mazeron and Suit [9] | 70 | 14 | 20% | Fong et al. [10] | 12 | 2 | 17% | Daigeler et al. [11] | 28 | 6 | 21% | Behranwala et al. [12] | 27 | 5 | 19% |
| Total | 144 | 32 | 22% |
| Clear cell | | | | Review Mazeron and Suit [9] | 40 | 11 | 28% | Daigeler et al. [11] | 14 | 3 | 21% | Behranwala et al. [12] | 25 | 1 | 4% |
| Total | 79 | 15 | 19% |
| NOS | | | | Mazeron and Suit [9] | 42 | 2 | 5% | Fong et al. [10] | 27 | 0 | 0% | Daigeler et al. [11] | 268 | 2 | 1% | Behranwala et al. [12] | 10 | 1 | 10% |
| Total | 347 | 5 | 1% |
| Dermatofibrosarcoma Protuberans | | | | Daigeler et al. [11] | 48 | 1 | 2% | Behranwala et al. [12] | 43 | 1 | 2% |
| Total | 91 | 2 | 2% |
|
|